Idiopathic thrombocytopenic purpura News and Research

RSS
Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Novel therapeutic approaches for various forms of thrombocytopenia

Novel therapeutic approaches for various forms of thrombocytopenia

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

FDA approves GSK's Promacta (Eltrombopag)

FDA approves GSK's Promacta (Eltrombopag)

Men get autoimmune diseases, too!

Men get autoimmune diseases, too!

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

Costly IVIg could be replaced with synthetic blood product

Costly IVIg could be replaced with synthetic blood product